$13.33
▲ +2.5% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Alpha Tau Medical Treats First Immunocompromised Patient in Alpha DaRT Study
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Overview
52-week range
$2.81
$12
100% of range
Avg surprise (last 3)
-31.3%
Avg reaction (last 2)
+4.0%
50% positive
Latest IV / EM
102%
EM ±23.3% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 18, 2026 | Mar/2026 | $-0.26 | $-0.13 | -100.0% | -116.7% | -3.2% | earnings |
| Mon Aug 11, 2025 | Jun/2025 | $-0.13 | $-0.12 | -8.3% | — | — | earnings |
| Mon May 19, 2025 | Mar/2025 | $-0.12 | $-0.14 | +14.3% | — | +11.1% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.14 | -$0.13 | -7.7% |